NCT01684397View on ClinicalTrials.gov

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

November 21, 2012

Primary Completion Date

January 20, 2026

Study Completion Date

January 20, 2026

Conditions
Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer
Interventions
BIOLOGICAL

Bevacizumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pazopanib Hydrochloride

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (5)

14263

Roswell Park Cancer Institute, Buffalo

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

53226

Medical College of Wisconsin, Milwaukee

66205

The University of Kansas Cancer Center, Westwood

482018

Karamanos Cancer Institute, Detroit

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT01684397 - Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter